KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to -$15.9 million.

  • Emergent BioSolutions' Cash from Financing Activities rose 91.18% to -$15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year increase of 88.05%. This contributed to the annual value of -$190.0 million for FY2024, which is 64.53% up from last year.
  • As of Q3 2025, Emergent BioSolutions' Cash from Financing Activities stood at -$15.9 million, which was down 148.44% from -$6.4 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Cash from Financing Activities peaked at $353.1 million during Q4 2022, and registered a low of -$486.9 million during Q2 2023.
  • Its 3-year average for Cash from Financing Activities is -$68.0 million, with a median of -$10.5 million in 2023.
  • In the last 5 years, Emergent BioSolutions' Cash from Financing Activities tumbled by 4,682.61% in 2021 and then spiked by 4,686.00% in 2022.
  • Emergent BioSolutions' Cash from Financing Activities (Quarterly) stood at -$110.0 million in 2021, then surged by 421.00% to $353.1 million in 2022, then tumbled by 98.67% to $4.7 million in 2023, then plummeted by 89.36% to $500,000 in 2024, then spiked by 91.18% to -$15.9 million in 2025.
  • Its last three reported values are -$15.9 million in Q3 2025, -$6.4 million for Q2 2025, and -$400,000 during Q1 2025.